Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, B-Cell, Marginal Zone 12 Lymphoma, Mantle-Cell 6 Lymphoma, Large B-Cell, Diffuse 4 Recurrence 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1

Interventions

Cyclophosphamide 27 fludarabine 18 Rituximab 17 obinutuzumab 11 venetoclax 9 Bendamustine Hydrochloride 9 Lenalidomide 8 zanubrutinib 6 Prednisone 6 Doxorubicin 6 Blood Specimen Collection 6 pembrolizumab 5 fludarabine phosphate 5 Biopsy 5 ibrutinib 4 glofitamab 4 Vincristine 4 Trimethoprim, Sulfamethoxazole Drug Combination 4 Exercise 4 loncastuximab tesirine 3 gamma-Globulins 3 axicabtagene ciloleucel 3 acalabrutinib 3 Temozolomide 3 Surveys and Questionnaires 3 Palliative Care 3 Mycophenolic Acid 3 Methotrexate 3 Mesna 3 Magnetic Resonance Spectroscopy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lymphoma × orelabrutinib × Clear all

NCT07441993 2026-03-02

MZL-IIT-O

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting

Lymphoma, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon ⚡